Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 90/100

Failure Rate

35.7%

5 terminated/withdrawn out of 14 trials

Success Rate

37.5%

-49.1% vs industry average

Late-Stage Pipeline

7%

1 trials in Phase 3/4

Results Transparency

67%

2 of 3 completed trials have results

Key Signals

4 recruiting2 with results

Enrollment Performance

Analytics

Phase 1
10(71.4%)
Phase 2
2(14.3%)
N/A
1(7.1%)
Phase 3
1(7.1%)
14Total
Phase 1(10)
Phase 2(2)
N/A(1)
Phase 3(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (14)

Showing 14 of 14 trials
NCT05476939Phase 3Recruiting

Biological Medicine for Diffuse Intrinsic Pontine Glioma (DIPG) Eradication 2.0

Role: collaborator

NCT03793478Phase 1Active Not Recruiting

Safety and Efficacy of Quizartinib in Children and Young Adults With Acute Myeloid Leukemia (AML), a Cancer of the Blood

Role: collaborator

NCT02613962Not ApplicableCompleted

Proof -of -Concept Study To Stratify Targeted Therapies Adapted To Molecular Profiling

Role: collaborator

NCT05429502Phase 1Terminated

Study of Efficacy and Safety of Ribociclib (LEE011) in Combination With Topotecan and Temozolomide (TOTEM) in Pediatric Patients With Relapsed or Refractory Neuroblastoma and Other Solid Tumors

Role: collaborator

NCT05751044Phase 1Recruiting

HEM-iSMART-B: Dasatinib + Venetoclax + Dexamethasone + Cyclophosphamide and Cytarabine in Pediatric Patients With Relapsed or Refractory Hematological Malignancies

Role: collaborator

NCT05745714Phase 1Recruiting

HEM-iSMART-C: Ruxolitinib + Venetoclax + Dexamethasone + Cyclophosphamide and Cytarabine in Pediatric Patients With Relapsed or Refractory Hematological Malignancies

Role: collaborator

NCT05658640Phase 1Recruiting

HEM iSMART-D: Trametinib + Dexamethasone + Chemotherapy in Children With Relapsed or Refractory Hematological Malignancies

Role: collaborator

NCT06679582Phase 1Terminated

Luveltamab Tazevibulin (STRO-002) in Infants and Children < 12 Years of Age With Relapsed/Refractory CBFA2T3::GLIS2 AML

Role: collaborator

NCT02303821Phase 1Completed

Study of Carfilzomib in Combination With Induction Chemotherapy in Children With Relapsed or Refractory Acute Lymphoblastic Leukemia

Role: collaborator

NCT05740449Phase 1Withdrawn

HEM-iSMART-A: Decitabine / Venetoclax and Navitoclax in Pediatric Patients With Relapsed or Refractory Hematological Malignancies

Role: collaborator

NCT01887522Phase 2Terminated

Study of Vinblastine in Combination With Nilotinib in Children, Adolescents, and Young Adults

Role: collaborator

NCT00306202Phase 1Completed

Study of Dasatinib in Children and Adolescents With Relapsed or Refractory Leukemia

Role: collaborator

NCT02233049Phase 2Unknown

Biological Medicine for Diffuse Intrinsic Pontine Glioma (DIPG) Eradication

Role: collaborator

NCT00742495Phase 1Terminated

Pharmacokinetic Study of Forodesine in Children With Relapsed or Refractory T-cell or B-cell Precursor Acute Lymphoblastic Leukaemia or T-cell Non- Hodgkin's Lymphoma.

Role: collaborator

All 14 trials loaded